Új vizsgálatok, publikációk, preprintek és pályázatok ezen a célponton, hónapról hónapra.
Vizsgálat
Revumenib, Azacitidine, and VENetoclax in Newly Diagnosed KMT2A-Rearranged AML
2026. dec. 1.· PHASE2 · NOT_YET_RECRUITING· CTGOV
Vizsgálat
A Phase IB Trial of Subcutaneous Blinatumomab in Combination With Revumenib for Patients With KMT2A-rearranged Acute Lymphoblastic Leukemia
2026. nov. 18.· PHASE1 · NOT_YET_RECRUITING· CTGOV
Publikáció
Frequent FLT3 and IDH co-mutations in acute myeloid leukemia with mutated NPM1, NUP98 rearrangement, and KMT2A partial tandem duplication but not rearrangement: potential for combined targeted therapy.
2026. nov. 5.· Haematologica· PUBMED
Publikáció
Complex and Cryptic KMT2A::MLLT10 Rearrangements in Acute Myeloid Leukemia Resolved by Optical Genome Mapping.
2026. nov. 1.· Genes, chromosomes & cancer· PUBMED
Publikáció
Decitabine plus busulfan-cyclophosphamide versus busulfan-cyclophosphamide myeloablative conditioning before allogeneic haematopoietic stem cell transplantation for reducing risk of relapse in adult KMT2A‑rearranged leukaemia in China: an open-label, multicentre, randomised phase 3 trial.
2026. nov. 1.· The Lancet. Haematology· PUBMED
Publikáció
Targeting menin dependency in acute leukemias: the role of revumenib in NPM1-mutated and KMT2A/NUP98-rearranged disease.
2026. okt. 29.· Future oncology (London, England)· PUBMED
Publikáció
Genome-Wide and Multi-Omics Analysis Identified DNA-Interacting Circular RNA circFOXK2 as MLL1 Regulator for Histone H3K4 Methylation in Pancreatic Ductal Adenocarcinoma.
2026. okt. 29.· Advanced science (Weinheim, Baden-Wurttemberg, Germany)· PUBMED
Publikáció
Pre-transplant immunotherapy and MRD dynamics affect post-transplant prognosis in KMT2A-rearranged B-ALL patients.
2026. okt. 28.· Bone marrow transplantation· PUBMED
Publikáció
Comparative analysis of KMT2A fusions in human models of acute myeloid leukemia.
2026. okt. 24.· Experimental hematology· PUBMED
Publikáció
LIN28B is essential for human fetal B-lymphopoiesis and initiation of KMT2A::AFF1 infant leukemia.
2026. okt. 22.· Blood· PUBMED
Vizsgálat
S243249 Monotherapy in Patients With Relapsed or Refractory Acute Leukemia With a KMT2A or NUP98 Translocation or Relapsed or Refractory AML With NPM1c Mutation
2026. okt. 20.· PHASE1_PHASE2 · NOT_YET_RECRUITING· CTGOV
Publikáció
The NG2-ITGA4 axis regulates Rho GTPases and leukemic aggressiveness in KMT2A-r B-ALL and is targetable with natalizumab.
2026. okt. 15.· Blood· PUBMED
Vizsgálat
Testing Blinatumomab With or Without Revumenib in Patients With B-cell Acute Lymphoblastic Leukemia With a Genetic Change Requiring More Treatment
2026. okt. 14.· PHASE2 · NOT_YET_RECRUITING· CTGOV
Publikáció
Three-Way Chromosomal Translocation Involving KMT2A::MLLT3 in AML: A Case Report and Genomic Characterization.
2026. okt. 12.· Cytogenetic and genome research· PUBMED
Vizsgálat
Ziftomenib for the Treatment of Patients With NPM1 Mutated or KMT2A Rearranged Acute Myeloid Leukemia Not Eligible for Standard Therapy
2026. okt. 1.· PHASE2 · RECRUITING· CTGOV
Vizsgálat
A Study of CHM-029 in Participants With NPM1 Mutated, KMT2A or NUP98 Rearranged AML
2026. szept. 28.· PHASE1 · RECRUITING· CTGOV
Publikáció
Targeting tomorrow: Evaluation of novel agents for infants with KMT2A-rearranged acute lymphoblastic leukaemia.
2026. szept. 22.· Blood reviews· PUBMED
Publikáció
Acute Myeloid Leukemia With KMT2A Amplification: A TP53-Alteration-Enriched Subgroup Associated With Chromoanagenesis and Poor Prognosis.
2026. szept. 17.· Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc· PUBMED
Publikáció
Cuplike nuclei and bimodal CD34 expression in adult KMT2A-rearranged pro-B acute lymphoblastic leukemia.
2026. szept. 10.· Blood· PUBMED
Publikáció
Measurable residual KMT2A partial tandem duplication before allogeneic stem cell transplantation in acute myeloid leukemia.
2026. szept. 3.· Haematologica· PUBMED
Vizsgálat
Ziftomenib + Mezigdomide in Adolesc. and Adults w/ R/R AML
2026. szept. 2.· PHASE1 · RECRUITING· CTGOV
Publikáció
Spatial Lineage Divergence at Diagnosis in a Pediatric KMT2A-Rearranged Leukemia Presenting with Concurrent AML and B-LBL.
2026. aug. 27.· Pediatric and developmental pathology : the official journal of the Society for Pediatric Pathology and the Paediatric Pathology Society· PUBMED
Publikáció
Clinicomolecular features and clonal evolution of KMT2A-PTD AML: prognostic impact of concurrent FLT3-ITD under 2022 ELN risk stratification.
2026. aug. 25.· Blood cancer journal· PUBMED
Publikáció
Successful treatment of relapsed KMT2A rearranged AML with central nervous system involvement using revumenib in combination with venetoclax and azacitidine: A case report.
2026. aug. 24.· Therapeutic advances in hematology· PUBMED
Publikáció
Modeling KRAS mutations in KMT2A::MLLT3 acute myeloid leukemia promotes leukemic progression and transcriptional rewiring.
2026. aug. 18.· Leukemia· PUBMED
Publikáció
[KMT2A-rearranged acute lymphoblastic leukemia with lineage switch following relapse: a case report and literature review].
2026. aug. 14.· Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi· PUBMED
Publikáció
A novel KMT2A::AFF1-derived fusion circRNA regulates mitochondrial metabolism in t(4;11) B-cell acute lymphoblastic leukemia.
2026. aug. 13.· Haematologica· PUBMED
Publikáció
A Case of Acute Myeloid Leukemia, Myelodysplasia-Related (AML-MR) with Immunophenotypic Features Suggestive of B/Myeloid Mixed-Phenotype Acute Leukemia (MPAL), Harboring Multiple KMT2A Gene Amplifications.
2026. aug. 11.· International journal of molecular sciences· PUBMED
Publikáció
Fusion-subtype and single-cell analyses refine the interpretation of HDAC8 dependency in KMT2A-rearranged AML.
2026. aug. 7.· Leukemia· PUBMED
Publikáció
Discovery and preclinical activity of the menin-KMT2A inhibitor ziftomenib in acute leukemia models.
2026. aug. 6.· Blood· PUBMED